Ebixa Treatment Initiation Pack
Ebixa Treatment Initiation Pack Uses, Dosage, Side Effects, Food Interaction and all others data.
Persistent activation of N-methyl-D-aspartate (NMDA) receptors in Central Nervous System by the excitatory amino acid glutamate has been hypothesized to contribute to the symptomatology of Alzheimer's disease. Ebixa Treatment Initiation Pack is postulated to exert its therapeutic effect through its action as a low to moderate affinity as an uncompetitive (open-channel) NMDA receptor antagonist which binds preferentially to the NMDA receptor-operated cation channels.
General effects
This drug inhibits calcium influx into cells that is normally caused by chronic NMDA receptor activation by glutamate . This leads to the improvement of Alzheimer's dementia symptoms, demonstrated by increased cognition and other beneficial central nervous system effects .
Effects on neuroplasticity
Trade Name | Ebixa Treatment Initiation Pack |
Availability | Prescription only |
Generic | Memantine |
Memantine Other Names | Memantina, Memantine, Memantinum |
Related Drugs | donepezil, Aricept, Namenda, rivastigmine, vitamin e, Exelon |
Type | |
Formula | C12H21N |
Weight | Average: 179.3018 Monoisotopic: 179.167399677 |
Protein binding | The protein binding for memantine is about 45% . |
Groups | Approved, Investigational |
Therapeutic Class | Anti - Alzheimer drugs, Drugs for Dementia |
Manufacturer | Lundbeck Limited |
Available Country | United Kingdom |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
Ebixa Treatment Initiation Pack is used for the treatment of all froms of dementia of the Alzheimer's type. Ebixa Treatment Initiation Pack may also be used for other types of dementia.
Ebixa Treatment Initiation Pack is also used to associated treatment for these conditions: Alzheimer's Disease (AD), Moderate-to-severe Alzheimer's Disease, Mild Vascular dementia, Moderate Alzheimer's Type Dementia, Moderate Vascular dementia, Severe Alzheimer's Type Dementia
How Ebixa Treatment Initiation Pack works
Continuous activation of the N-methyl-D-aspartate (NMDA) receptors in the central nervous system caused by glutamate is thought to cause some of the Alzheimer's disease symptoms. This overactivation is thought to contribute to neurotoxicity due to the excitatory properties of glutamate . The pharmacological effect of memantine likely occurs via the drug's behavior as an uncompetitive (open-channel) NMDA receptor antagonist, preventing glutamate action on this receptor. Ebixa Treatment Initiation Pack has a preference for the NMDA receptor-operated cation channels. Despite these antagonist effects, memantine has not been proven to prevent or retard the neurodegeneration seen in patients diagnosed with Alzheimer’s disease .
Dosage
Ebixa Treatment Initiation Pack dosage
The recommended maintenance dose of Ebixa Treatment Initiation Packfor adults and older patients is 20 mg every day. In order to lower the risk of side effects, the dose should be achieved by upward titration with 5 mg per week over 3 weeks, achieving the maintenance dose of 20 mg/day from the start of week 4 according to the following dosage guideline:
Week 1 (Everyday):Morning- 5 mg (1 tablet),Night- No dose
Week 2 (Everyday):Morning- 5 mg (1 tablet),Night- 5 mg (1 tablet)
Week 3 (Everyday):Morning- 10 mg (2 tablets),Night- 5 mg (1 tablet)
Week 4 and onwards (Everyday):Morning- 10 mg (2 tablets),Night- 10 mg (2 tablets)
Missed Dose: If any dose is missed, just wait and take the next dose at the usual time. Do not double the dose to compensate for the missed dose.
Side Effects
Most frequent side effects (frequency of 2% or less) include hallucination, confusion, dizziness, headache and fatigue. Occasional side effects include anxiety, hypertonus (heightened muscle tension), vomiting, bladder infections and increased sexual drive. If there is a history of epileptic seizures, there is a slight chance that Ebixa Treatment Initiation Pack may increase the probability of an attack.
Toxicity
LD50
Oral LD50, mouse 437-498 mg/kg Oral LD50, rat 328-370 mg/kg
Carcinogenesis, Mutagenesis, Impairment of Fertility
No evidence of carcinogenicity was seen in mouse and rat models administered memantine at doses equivalent to supratherapeutic human doses . Additionally, no genotoxic potential was noted when a battery of assays was performed. No effects on fertility or reproductive performance were noted in rats given to 18 mg/kg/day (equivalent to 9 times the maximum recommended human dose) orally from 14 days preceding mating through gestation and lactation in females, or for 60 preceding mating activity in males animals .
Use in pregnancy
This drug is considered a pregnancy category B drug, meaning no sufficiently controlled and adequate studies of memantine in pregnant women have been performed. This drug should be taken during pregnancy only if the potential benefit justifies the possible fetal risk .
Use in nursing
It is unknown whether memantine is excreted in human milk. Due to that fact that many drugs are found excreted in human milk, caution should be observed when this drug is taken by a nursing mother .
Precaution
Caregivers should be instructed in the recommended administration (twice per day for doses above 5 mg) and dose escalation (minimum interval of one week between dose increases). If the patients suffer from kidney dysfunction, the kidney function should be monitored at regular basis.Neurological Conditions-
- Seizures: Ebixa Treatment Initiation Pack has not been systematically evaluated in patients with a seizure disorder. One clinical trial shows that seizures occurred in 0.2% of patients treated with Ebixa Treatment Initiation Pack and 0.5% of patients treated with placebo.
- Carcinogenesis, Mutagenesis and Impairment of Fertility: Study shows that no risk of carcinogenesis, mutagenesis and impairment of fertility are caused after Ebixa Treatment Initiation Pack use.
Interaction
Amantadine, Anticholinergics, Anticonvulsives, Baclofen, Barbiturates, Cimetidine, Dantrolene, Dextromethorphan, Dopaminergic, Hydrochlorothiazide, Ketamine, Neuroleptics, Nicotine, Procainamide, Quinidine, Quinine, Ranitidine.
Food Interaction
- Take with a full glass of water.
- Take with or without food. The absorption is unaffected by food.
Ebixa Treatment Initiation Pack Drug Interaction
Moderate: quetiapineUnknown: donepezil, aspirin, aspirin, ubiquinone, duloxetine, apixaban, omega-3 polyunsaturated fatty acids, pregabalin, metoprolol, metoprolol, polyethylene glycol 3350, mirabegron, levothyroxine, acetaminophen, cyanocobalamin, ascorbic acid, cholecalciferol, alprazolam, cetirizine
Ebixa Treatment Initiation Pack Disease Interaction
Volume of Distribution
The mean volume of distribution of memantine is 9-11 L/kg .
Elimination Route
After an oral dose, memantine is well absorbed. Its peak drug concentrations are attained in about 3-7 hours. Ebixa Treatment Initiation Pack shows linear pharmacokinetics when given at normal therapeutic doses. This drug can be taken without regard to food, as there is no effect of food on memantine absorption .
Half Life
Within the range of 60-100 hours .
The terminal elimination half-life was significantly increased in patients with moderate to severe renal impairment, in comparison with patients with normal renal function . Exercise caution when this drug is administered to patients with renal dysfunction.
Clearance
This drug is cleared by active tubular secretion in the kidneys. Tubular reabsorption of this drug is pH dependent .
Elimination Route
This drug is mainly excreted in the urine. Approximately 48% of administered memantine is excreted unchanged in urine .
The remainder of the drug is metabolized to three main metabolites. These metabolites are the N-glucuronide conjugate, 6-hydroxy memantine, and 1-nitroso-deaminated memantine, which show minimal NMDA receptor antagonist activity .
Pregnancy & Breastfeeding use
Pregnancy Category B. Yet there are no adequate and well controlled studies of Ebixa Treatment Initiation Pack in pregnant women. Ebixa Treatment Initiation Pack should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether Ebixa Treatment Initiation Pack is excreted in human breast milk. Because many drugs are excreted in human milk, caution should be exercised when Ebixa Treatment Initiation Pack is administered to a nursing mother.
Contraindication
Ebixa Treatment Initiation Pack Hydrochloride is contraindicated in patients with known hypersensitivity to Ebixa Treatment Initiation Pack Hydrochloride or to any excipients used in the formulation.
Special Warning
In case of renal impairment: A target dose of 5 mg BID is recommended in patients with severe renal impairment (creatinine clearance: 5-29 ml/min).
In case of hepatic impairment: No dosage adjustment is needed in patients with mild or moderate hepatic impairment. Ebixa Treatment Initiation Pack should be administered with caution to patients with severe hepatic impairment.
Acute Overdose
Symptoms: Agitation, asthenia, bradycardia, vomiting, dizziness, vertigo, ECG changes, increased BP, visual hallucinations, confusion, lethargy, restlessness, slowed movement, somnolence, stupor, unsteady gait, weakness, loss of consciousness, psychosis, coma.
Management: Symptomatic and supportive treatment. May increase elimination by urinary acidification.
Storage Condition
Store in a cool and dry place, protected from light. Keep this medication out of reach of children.
Innovators Monograph
You find simplified version here Ebixa Treatment Initiation Pack
Ebixa Treatment Initiation Pack contains Memantine see full prescribing information from innovator Ebixa Treatment Initiation Pack Monograph, Ebixa Treatment Initiation Pack MSDS, Ebixa Treatment Initiation Pack FDA label